New Competitor in MMJ Market sets High Standards
PI Financial is initiating coverage of Emblem (TSXV:EMC) with a BUY rating (Risk rating: SPECULATIVE) with a 12-month target of $3.25. As quoted in the report: Emblem Corp. is a fully integrated Canadian medical marijuana, healthcare and cannabinoid-based pharmaceutical company licensed to carry on business as a producer and seller of medical cannabis. Strong management. … Continued
PI Financial is initiating coverage of Emblem (TSXV:EMC) with a BUY rating (Risk rating: SPECULATIVE) with a 12-month target of $3.25.
As quoted in the report:
Emblem Corp. is a fully integrated Canadian medical marijuana, healthcare and cannabinoid-based pharmaceutical company licensed to carry on business as a producer and seller of medical cannabis.
Strong management. Gordon Fox leads a strong team of professionals with deep roots in the medical field. Harvey Shapiro, President of GrowWise a joint venture partner, co-founded an independent pharmacy chain with Gordon Fox as well as co-founding Dynacare – a medical diagnostic services company.John Stewart, President of Emblem’s pharmaceutical division was CEO of Purdue Pharma Canada.
Emblem has a state-of-the-art facility in Ontario, which boasts the most up-to-date growing technology and is built on clean room standards. The facility is able to produce 700kg of MMJ and will expand shortly to 2,100kg by early 2017.
